The mechanisms and regulatory factors that control the development of oligodendrocytes and the synthesis of myelin are poorly understood. The present project represents the next steps in our ongoing research on the regulation of oligodendrocyte development by 3','5 -cyclic AMP (cAMP), using tissue cultures of oligodendrocytes and oligodendrocyte precursors from rat brain. In previous studies, we have shown that cAMP analogs and agents that elevate intracellular cAMP accelerated the development of oligodendrocytes and increase the expression of myelin proteins, lipids and mRNAs. In our first specific aim, we will complete ongoing studies on the regulation of myelin proteins 2',3' cyclic nucleotide 3'phosphohydrolase (CNP), myelin basic protein (MBP), myelin proteolipid protein (PLP), DM-20 protein and myelin-associated glycoprotein (MAG) under uninduced and cAMP-induced conditions. Second, we will use antibodies to cAMP and quantitative single-cell cytofluorimetry to determine whether there is an endogenous increase in intracellular cAMP levels in glial cells as they develop into oligodendrocytes in the absence of experimental inducers. Third, we will use the specific cAMP antagonist, the Rp-diastereomer of adenosine 3'-5' cyclic phosphorothioate (Rp-cAMPS), to determine whether elevation of intracellular cAMP is a necessary precondition for oligodendrocyte development. Fourth, we will identify agonist that induce the intracellular production of cAMP in oligodendrocytes and precursors. And fifth, we will used an in vitro model system of autoimmune demyelination in aggregate cultures to determine whether cAMP analog or agents that elevate intracellular cAMP can be used to promote remyelination. These studies will define the mechanisms by which the regulatory molecule, cAMP, induces the activity of myelin-related genes i oligodendrocytes; clarify how oligodendrocyte development is regulated; and utilized this information to test possible procedures for promoting remyelination.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Program Officer
Kerza-Kwiatecki, a P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Skorupa, A F; Brezinski, S C; Lesh, G et al. (2001) Expression of Golli mRNA during development in primary immune lymphoid organs of the rat. J Neuroimmunol 119:64-72
Wiemelt, A P; Lehtinen, M; McMorris, F A (2001) Agonists calcitonin, corticotropin-releasing hormone, and vasoactive intestinal peptide, but not prostaglandins or beta-adrenergic agonists, elevate cyclic adenosine monophosphate levels in oligodendroglial cells. J Neurosci Res 65:165-72
Shen, S; Wiemelt, A P; McMorris, F A et al. (1999) Retinal ganglion cells lose trophic responsiveness after axotomy. Neuron 23:285-95
Hanson Jr, M G; Shen, S; Wiemelt, A P et al. (1998) Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro. J Neurosci 18:7361-71
Mewar, R; McMorris, F A (1997) Expression of insulin-like growth factor-binding protein messenger RNAs in developing rat oligodendrocytes and astrocytes. J Neurosci Res 50:721-8
Wiemelt, A P; Engleka, M J; Skorupa, A F et al. (1997) Immunochemical visualization and quantitation of cyclic AMP in single cells. J Biol Chem 272:31489-95
McMorris, F A; McKinnon, R D (1996) Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease. Brain Pathol 6:313-29
Vemuri, G S; McMorris, F A (1996) Oligodendrocytes and their precursors require phosphatidylinositol 3-kinase signaling for survival. Development 122:2529-37
Shinar, Y; McMorris, F A (1995) Developing oligodendroglia express mRNA for insulin-like growth factor-I, a regulator of oligodendrocyte development. J Neurosci Res 42:516-27